Summary Human colon adenocarcinoma cells (LoVo) (Arcamone et al., 1989; Kopka et al., 1985) , is a novel antitumour compound currently being investigated in phase I clinical trials ( Figure 1 ).
The mechanism of action responsible for the antitumour activity of this compound remains to be established. Like distamycin A, FCE 24517 binds preferentially to adeninethymine rich sequences in the minor groove of P-DNA (Broggini et al., 1991) . Both compounds inhibit the binding of transcription factors which recognise adenine-thymine rich boxes, but have no effects on the guanine-cytosine rich ones (Broggini et al., 1989; . It was reported that FCE 24517 directly and specifically inhibits human DNA ligase (Montecucco et al., 1991) . This effect is not shared by distamycin A. The parent compound distamycin A has a very low cytotoxic activity and is inactive as an antitumour agent; the insertion of the alkylating benzoyl-mustard moiety on the distamycin A skeleton confers to FCE 24517 a potent antiproliferative activity in vitro and antineoplastic activity in vivo against a variety of experimental tumours of both murine and human origin (Pezzoni et al., 1991) .
Despite the fact that FCE 24517 contains an alkylating moiety, its mode of action appears to be different from that of classical alkylating agents. It was recently reported that, in contrast with the alkylating agents currently used, FCE 24517 does not alkylate guanine N7 but only adenine N3 (Broggini et al., 1991) .
When dealing with novel antitumour compounds, the availability of resistant cell sublines is of the utmost importance for obtaining information as to their mode of action, as well as identifying the resistance pattern that can emerge after treatment. For this purpose, we have isolated a human colon adenocarcinoma cell line selected after repeated in vitro treatment with FCE 24517 (LoVo/24517). All the characterisation experiments with this cell line have been carried out in comparison with the doxorubicin (DX) resistant cell line, LoVo/Dx. LoVo/DX cells, selected and characterised in our laboratory (Grandi et al., 1986) , present the classical multidrug resistant (MDR) phenotype, with overexpression of mdr-l mRNA and DNA (Ballinari et al., 1988) and strong positivity of monoclonal antibodies directed against p170 (Dinota et al., 1990) . Since the cytotoxic activity of FCE 24517 was markedly reduced against LoVo/DX cells, compared with the parent line (Pezzoni et al., 1991) , it was anticipated that treatment with this compound would also select a MDR population.
To test this possibility, the following parameters have been investigated in the LoVo/24517 and LoVo/DX cell lines: (i) mdr-J mRNA expression; (ii) patterns of cross-resistance to other anticancer drugs; and (iii) influence of the addition of verapamil, tamoxifen, cyclosporin A or nicergoline, known modulators of MDR (Rogan et al., 1984; Ramu et al., 1984; Meador et al., 1987; Carfagna & Rossi, 1989) 
Cell lines
The human colon adenocarcinoma cell line, LoVo (Drewinko et al., 1976) , its sublines resistant to FCE 24517, LoVo/ 24517, and to doxorubicin, LoVo/DX (Grandi et al., 1986) were maintained in Ham's F12 medium (GIBCO, Grand Island Biological Co., Grand Island, NY, USA) supplemented with 10% foetal bovine serum (Flow Laboratories, UK), 1% vitamins (vitamins BME solution, 100 x, GIBCO) and 1% L-glutamine 200 mM (GIBCO).
LoVo/24517 cells were maintained in the absence of FCE 24517 and LoVo/DX cells in the presence of DX (100 ng ml-').
Growth rate Doubling times were evaluated. Cells at a concentration of 15,000 cells cm2 were seeded into 16mm plastic wells (Falcon; Becton Dickinson, Milan, Italy). Cell growth was monitored daily for 10 days by counting the cells with a ZM Coulter Counter (Coulter Electronics Ltd, Northwell Drive, Luton, Beds, LU3 3RH, UK) beginning 24 h after plating and doubling times calculated. Cytotoxicity Cells were seeded in 35 mm plastic dishes at a concentration of 600 cells per dish; after 48 h cells were treated with the drugs for 4 h, then medium was replaced with fresh medium, and colonies were counted after 8-10 days using an optical microscope.
The concentration inhibiting 50% colonies growth (IC50) was calculated from dose-response curves and expressed as ng ml-1. mdr-mRNA expression Total cellular RNA was extracted by the guanidium isothiocyanate/cesium chloride centrifugation method (Maniatis et al., 1982) .
For Northern blot analysis 20 tg of total RNA was fractionated on 1% agarose gel containing 6.7% formaldehyde and transferred to nylon membranes (Gene-screen plus, New England Nuclear). The filters were hybridised for 16 h at 42°C in 50% formamide, 10% dextran sulfate, 1 M NaCI, 1% SDS (Sodium Dodecyl Sulfate), 100Ogml-' of denatured salmon sperm DNA and 106cpmml1' of denatured 32p_ labelled probe. After hybridisation the filters were washed sequentially in 2 x SSC (0.15 M Sodium Chloride and 0.015 M sodium citrate) at room temperature and in 2 x SSC 1% SDS at 65°C. The probes utilised were the 1.3 kb EcoRI/ SalI insert of pcDR.3 (Gros et al., 1986) containing the human mdr-J gene (Gros et al., 1986 ) and the 1.8 kb PstI insert of the murine actin gene. Both probes were 32P-labelled using the multiprime DNA labeling system and 32P-dCTP (Amersham, UK).
The autoradiographic signals for mdr-J expression were quantitated using an image analyser IBAS 2 (Kontron Electronic GHBH pc 386 MS-DOS) and the values were normalised with those obtained for a-actin. LoVo/24517 cells, the activity of FCE 24517 is only partially restored by the addition of each RMA. Conversely, a complete restoration of FCE 24517 cytotoxic activity was obtained testing LoVo/DX cells; the RI being reduced from 37.2 to 3.3-1.7. In both cell lines however, resistance to DX was completely restored after treatment with these RMAs: the marginal resistance observed in LoVo/24517 cells (RI = 4.3) being reduced to 1-2.8; whilst in LoVo/DX cells, the RI is reduced from 50.5 to 1.9-3.8.
Discussion
The fact that the cytotoxic activity of FCE 24517, a benzoylmustard derivative of distamycin A whose mode of action is not yet elucidated, was markedly reduced against MDR cells (Pezzoni et al., 1991) suggests that this novel structure is recognised by a p170-mediated extrusion mechanism. However, this paper demonstrates that exposure of LoVo cells to FCE 24517 does not select for the 'classical' p170-mediated mechanism of resistance.
A 56.3-fold FCE 24517 resistant subline (LoVo/24517) proved 25.5-fold resistant to vinblastine, but only marginally or no resistant to DX, VP-16 and to mAMSA and mdr-J mRNA expression was only elevated 2-fold. In apparent contrast, the classic LoVo/DX subline proved cross resistant to all these mdr-associated drugs and showed a 24-fold overexpression of mdr-J mRNA, but this subline also proved 33-fold cross resistant to FCE 24517. Indeed, both LoVo/ 24517 and LoVo/DX cells also showed cross resistance to the other distamycin A analogues tested.
Similar results have also been observed in the murine leukaemia L1210 cell line (Geroni et al., 1993) .
RMAs also had differential effects on the LoVo/24517 and LoVo/DX cells, proving more effective in modulating FCE 24517 cytotoxicity in the latter as opposed to the former subline. Conversely in combination with DX, the four RMAs were effective in completely restoring activity in both cell lines. Taken together, these data indicate that resistance selected after treatment with FCE 24517 in these LoVo sublines, can be only partially mediated through p170 overexpression.
The main mode of action, therefore, remains to be established and these LoVo sublines will prove valuable in these mechanistic studies. 
